Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Related MDCO
Earnings Scheduled For February 18, 2015
Catalysts To Watch For In RBC Capital's 2015 Top Small-Cap Biotechs
Related BMY
Fast Money Halftime Report Final Trade From March 5
What Analysts Said After Bristol-Myers' Quick Lung Drug Approval
Bristol-Myers' Drug Shows Impressive Data, Inks Deal - Analyst Blog (Zacks)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News


Related Articles (MDCO + BMY)

Around the Web, We're Loving...